HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis

doi:10.1016/0016-5085(95)90463-8

Gastroenterology

Volume 108, Issue 3, March 1995, Pages 870-878

https://doi.org/10.1016/0016-5085(95)90463-8 Get rights and content

Abstract

$Background/Aims$ : The association between primary sclerosing cholangitis (PSC) and the HLA haplotype A1, B8, DR3, DQ2 is well established. During the last few years, several additional HLA associations have been suggested in PSC. Furthermore, two different HLA-DR specificities have been reported to be markers for rapid disease progression. Our aim was to critically evaluate all of the current and as yet mostly unconfirmed HLA class II issues in PSC.

$Methods$ : Seventy-five Swedish patients with PSC were HLA-DR and HLA-DQ genotyped.

$Results$ : Of the recently described HLA associations in PSC, the association with the DRB1∗1301, DQA1∗ 0103, DQB1∗0603 haplotype was decisively confirmed, whereas the DRB1∗04 specificity was only slightly under-represented and the frequency of DR2 was neutral. The association with codon 38 of DRB genes was secondary to the DRB3∗0101 association. HLA-DR and HLA-DQ alleles were not found to be markers for disease progression.

$Conclusions$ : The HLA-associated genetic susceptibility to PSC cannot be attributed to specific amino acid positions of the DRβ chains. The highly discrepant results obtained in two previously reported studies and the present investigation indicate that HLA class II alleles are not markers for a more aggressive clinical course in PSC.

References (38)

DA Brewerton et al.
Ankylosing spondylitis and HLA-A 27
Lancet
(1973)
N Langdon et al.
Genetic markers in narcolepsy
Lancet
(1984)
N Langdon et al.
Genetic markers in narcolepsy
Lancet
(1984)
KD Lindor et al.
Enhanced autoreactivity of T-lymphocytes in primary sclerosing cholangitis
Hepatology
(1987)
RWG Chapman et al.
Long-standing asymptomatic primary sclerosing cholangitis
Dig Dis Sci
(1989)
O Olerup et al.
Inability to attribute susceptibility to primary sclerosing cholangitis to specific amino acid position of the HLA-DRw52a allele
N Engl J Med
(1991)
B Carlsson et al.
HLA-DR-DQ haplotypes defined by restriction fragment length analysis—correlation to serology
Hum Immunol
(1987)
JL Bidwell et al.
A DNA-RFLP typing system which positively identifies serologically well-defined and ill-defined HLA-DR and -DQ alleles, including DRw10
Transplantation
(1988)
L Schlosstein et al.
High association of an HLA antigen, W27, with ankylosing spondylitis
N Engl J Med
(1973)
T Juji et al.
HLA antigens in Japanese patients with narcolepsy
Tissue Antigens
(1984)
JA Todd et al.
HLA-DQ_β gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus
Nature
(1987)

GT Hom et al.

Allelic sequence variation of the HLA-DQ loci: relationship to serology and to insulin-dependent diabetes susceptibility

O Olerup et al.

Different amino acids at position 57 of the HLA-DQβ chain associated with susceptibility and resistance to IgA deficiency

Nature

(1990)

O Olerup et al.

Shared HLA class II associated genetic susceptibility and resistance, related to the HLA-DQB1 gene, in IgA deficiency and common variable immunodeficiency

PK Gregersen et al.

The shared epitope hypothesis

RNM MacSween et al.

Pathology of the liver

A Mandal et al.

Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium

Gastroenterology

(1994)

RH Wiesner et al.

Clinicopathologic features of the syndrome primary sclerosing cholangitis

Gastroenterology

(1980)

E Schrumpf et al.

HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease

Scand J Gastroenterol

(1982)

EJ Prochazka et al.

Association of primary sclerosing cholangitis with HLA-DRw52a

N Engl J Med

(1990)

Cited by (81)

Indications and follow-up for autologous hematopoietic stem cell transplantation in multiple sclerosis: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in association with the Francophone Society of Multiple Sclerosis
2019, Bulletin du Cancer
Dans une démarche qui vise à uniformiser les procédures d’allogreffe et d’autogreffe de cellules souches hématopoïétiques, la Société francophone de greffe de moelle et thérapie cellulaire (SFGM-TC) a organisé les huitièmes ateliers d’harmonisation des pratiques en allogreffe de cellules souches hématopoïétiques en septembre 2017 à Lille. Dans le contexte de cet atelier, il a été développé et mis à jour les indications et le suivi des autogreffes de cellules souches hématopoïétiques dans la sclérose en plaques sous l’égide de la SFGM-TC et de la Société francophone de la sclérose en plaques.
The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 8th allogeneic hematopoietic stem cell transplantation clinical practices harmonization workshop series in September 2017 in Lille, France. In this article we give the indications of autologous stem cell transplantation in multiple sclerosis as well as recommendations regarding post-transplant follow-up of patients under the hospice of the SFGM-TC and the Francophone Society of Multiple Sclerosis.
Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management
2015, Clinical Gastroenterology and Hepatology
Citation Excerpt :
PSC has robust associations within the HLA complex, which provides further credence to the notion that immunity plays a role in its pathogenesis.22 Haplotypes with well-established associations with PSC include HLA-DRB1*1301-DQB1*0603, HLA-A1-B8-DRB1*0301-DQB1*0201, and HLA-DRB1*1501-DQB1*0602.23,24 Overall, there are 16 known genome-wide significant loci in PSC, including the HLA complex on chromosome 6.25–27
Primary sclerosing cholangitis (PSC) is a premalignant biliary tract disease that confers a significant risk for the development of cholangiocarcinoma (CCA). The chronic biliary tract inflammation of PSC promotes pro-oncogenic processes such as cellular proliferation, induction of DNA damage, alterations of the extracellular matrix, and cholestasis. The diagnosis of malignancy in PSC can be challenging because inflammation-related changes in PSC may produce dominant biliary tract strictures mimicking CCA. Biomarkers such as detection of methylated genes in biliary specimens represent noninvasive techniques that may discriminate malignant biliary ductal changes from PSC strictures. However, conventional cytology and advanced cytologic techniques such as fluorescence in situ hybridization for polysomy remain the practice standard for diagnosing CCA in PSC. Curative treatment options of malignancy arising in PSC are limited. For a subset of patients selected by using stringent criteria, liver transplantation after neoadjuvant chemoradiation is a potential curative therapy. However, most patients have advanced malignancy at the time of diagnosis. Advances directed at identifying high-risk patients, early cancer detection, and development of chemopreventive strategies will be essential to better manage the cancer risk in this premalignant disease. A better understanding of dysplasia definition and especially its natural history is also needed in this disease. Herein, we review recent developments in our understanding of the risk factors, pathogenic mechanisms of PSC associated with CCA, as well as advances in early detection and therapies.
Diagnosis and classification of primary sclerosing cholangitis
2014, Autoimmunity Reviews
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease of the liver and that is characterized by progressive inflammation, fibrosis, and stricturing of the intrahepatic and extrahepatic bile ducts. It is progressive in most patients and leads to cirrhosis. It is a rare disease, mostly affecting people of northern European descent, males greater than females. The diagnosis is best established by contrast cholangiography, which reveals a characteristic picture of diffuse, multifocal strictures and focal dilation of the bile ducts, leading to a beaded appearance. Inflammatory bowel disease (IBD) is present in ~ 75% of the patients with PSC, mostly ulcerative colitis (~ 85% of the cases). In addition to biliary cirrhosis, complications of PSC include dominant strictures of the bile ducts, cholangitis, cholangiocarcinoma, colon dysplasia and cancer in patients with IBD, gallbladder polyps and cancer, and hepatic osteodystrophy. The etiology of PSC is not clear, but studies are ongoing. The median survival without liver transplantation is 12 to 15 years after diagnosis. Currently there are no effective treatments except liver transplantation. Immunosuppressive medications have not been shown to be effective but antibiotics and anti-fibrotic agents seem promising.
Primary Sclerosing Cholangitis
2013, The Autoimmune Diseases: Fifth Edition
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disorder characterized by inflammation and progressive obliterative fibrosis of the intrahepatic and/or extrahepatic bile ducts which can lead to cirrhosis and complications related to portal hypertension. PSC is strongly associated with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), as well as an increased risk of hepatobiliary and colorectal malignancy. PSC has several important subtypes, chiefly small duct PSC and PSC-autoimmune hepatitis (PSC-AIH) overlap. The pathophysiology behind PSC is poorly understood, but is likely a complex interaction between genes and the environment. Mounting evidence suggests key immunologic components involved in the development and progression of PSC. Currently, there is no effective medical therapy for PSC and liver transplantation (LT) provides PSC patients with excellent long-term outcomes. Aside from LT in appropriate patients, recognition and treatment of co-morbid conditions and cancer surveillance remain key components to the management of patients with PSC.
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management
2013, Gastroenterology
Citation Excerpt :
Patients who have a first-degree relative with PSC have a 9- to 39-fold increased risk of development of the disease.14 In the past 2 decades, candidate gene studies associated specific HLAs with PSC, including the haplotypes HLA-DRB1*1501-DQB1*0602, HLA-DRB1*1301-DQB1* 0603, and HLA-A1-B8-DRB1*0301-DQB1*0201.58–61 Recent genome-wide association studies have also reported that the strongest genetic risk to PSC lies within the major histocompatibility complex, where the heritability represented by these loci is twice that of all other risk loci combined.62
Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is a complex liver disease that is heterogeneous in its presentation. PSC is characterized by chronic cholestasis associated with chronic inflammation of the biliary epithelium, resulting in multifocal bile duct strictures that can affect the entire biliary tree. Chronic inflammation leads to fibrosis involving the hepatic parenchyma and biliary tree, which can lead to cirrhosis and malignancy. The etiology of PSC is not fully understood, which in part explains the lack of effective medical therapy for this condition. However, we have begun to better understand the molecular pathogenesis of PSC. The recognition of specific clinical subtypes and their pattern of progression could improve phenotypic and genotypic classification of the disease. We review our current understanding of this enigmatic disorder and discuss important topics for future studies.
Primary sclerosing cholangitis
2012, Blumgart's Surgery of the Liver, Biliary Tract and Pancreas

View all citing articles on Scopus

^☆: Supported by grants from the Swedish Medical Research Council (projects 10137 and 10393), the Swedish Society of Medicine, and the Foundation of Professor Nanna Svartz.

View full text

HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis☆

Abstract

Lancet

Lancet

Lancet

Hepatology

Dig Dis Sci

N Engl J Med

Hum Immunol

Transplantation

High association of an HLA antigen, W27, with ankylosing spondylitis

N Engl J Med

HLA antigens in Japanese patients with narcolepsy

Tissue Antigens

HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus

Nature

Allelic sequence variation of the HLA-DQ loci: relationship to serology and to insulin-dependent diabetes susceptibility

Different amino acids at position 57 of the HLA-DQβ chain associated with susceptibility and resistance to IgA deficiency

Nature

Shared HLA class II associated genetic susceptibility and resistance, related to the HLA-DQB1 gene, in IgA deficiency and common variable immunodeficiency

The shared epitope hypothesis

Pathology of the liver

Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium

Gastroenterology

Clinicopathologic features of the syndrome primary sclerosing cholangitis

Gastroenterology

HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease

Scand J Gastroenterol

Association of primary sclerosing cholangitis with HLA-DRw52a

N Engl J Med

HLA-DQ_β gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus